Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial

Kristian Thorlund et al.

Summary: This article discusses the issues and flaws in a clinical trial of an oral therapeutic drug called molnupiravir, and suggests the need for independent external trials to determine the efficacy of this drug.

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2022)

添加到收藏夹

Review Virology

Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review

Sri Masyeni et al.

Summary: Broad-spectrum antiviral agents targeting viral RNA-dependent RNA polymerase (RdRp) are expected to play a key role in the treatment of COVID-19. Molnupiravir, a nucleoside analog, has shown significant efficacy in inhibiting the replication of SARS-CoV-2. However, its effect on host cell DNA is still under question. Administered orally, molnupiravir is expected to change the course of the COVID-19 pandemic.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Molnupiravir's authorisation was premature Regulatory decisions fall short of the wise stewardship required during a pandemic

James Brophy

BMJ-BRITISH MEDICAL JOURNAL (2022)

添加到收藏夹

Review Endocrinology & Metabolism

Molnupiravir in COVID-19: A systematic review of literature

Awadhesh Kumar Singh et al.

Summary: Molnupiravir has shown significant benefits in reducing hospitalization or death in mild COVID-19 cases, making it a potential important tool in combating SARSCoV-2. However, its efficacy in moderate to severe COVID-19 remains uncertain, requiring further studies for clarification.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2021)

添加到收藏夹

Article Medicine, General & Internal